You may have heard in the news that the NHS is doing a study that expects to almost halve the number of invasive procedures for bowel cancer by 2020, by...
Read moreLatest Articles
Heptares announced in a press release today that the first subject has been dosed in this ‘phase 1 clinical study of novel selective muscarinic M4 agonist in...
Read moreHMR offers high-precision QT measurement as a cost-effective alternative to thorough QT studies. In November 2015, HMR completed the iCardiac Site Certification...
Read moreThe French Ministry of Higher Education and Research has renewed our status as an approved research and development organisation until 2020. This allows French...
Read more